250 related articles for article (PubMed ID: 18021749)
1. Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2.
Golub AG; Yakovenko OY; Prykhod'ko AO; Lukashov SS; Bdzhola VG; Yarmoluk SM
Biochim Biophys Acta; 2008 Jan; 1784(1):143-9. PubMed ID: 18021749
[TBL] [Abstract][Full Text] [Related]
2. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
[TBL] [Abstract][Full Text] [Related]
3. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight.
Lolli G; Cozza G; Mazzorana M; Tibaldi E; Cesaro L; Donella-Deana A; Meggio F; Venerando A; Franchin C; Sarno S; Battistutta R; Pinna LA
Biochemistry; 2012 Aug; 51(31):6097-107. PubMed ID: 22794353
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2.
Golub AG; Bdzhola VG; Briukhovetska NV; Balanda AO; Kukharenko OP; Kotey IM; Ostrynska OV; Yarmoluk SM
Eur J Med Chem; 2011 Mar; 46(3):870-6. PubMed ID: 21276643
[TBL] [Abstract][Full Text] [Related]
6. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules.
Raaf J; Brunstein E; Issinger OG; Niefind K
Chem Biol; 2008 Feb; 15(2):111-7. PubMed ID: 18291315
[TBL] [Abstract][Full Text] [Related]
7. The dark side of protein kinase CK2 inhibition.
Cozza G; Meggio F; Moro S
Curr Med Chem; 2011; 18(19):2867-84. PubMed ID: 21651492
[TBL] [Abstract][Full Text] [Related]
8. Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2.
Gyenis L; Turowec JP; Bretner M; Litchfield DW
Biochim Biophys Acta; 2013 Jul; 1834(7):1352-8. PubMed ID: 23416530
[TBL] [Abstract][Full Text] [Related]
9. Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors.
Hundsdörfer C; Hemmerling HJ; Götz C; Totzke F; Bednarski P; Le Borgne M; Jose J
Bioorg Med Chem; 2012 Apr; 20(7):2282-9. PubMed ID: 22377675
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of synthetic 4'-hydroxyflavones-New CK2 inhibitors from flavone family.
Golub AG; Bdzhola VG; Ostrynska OV; Kyshenia IV; Sapelkin VM; Prykhod'ko AO; Kukharenko OP; Yarmoluk SM
Bioorg Med Chem; 2013 Nov; 21(21):6681-9. PubMed ID: 24011954
[TBL] [Abstract][Full Text] [Related]
11. New protein kinase CK2 inhibitors: jumping out of the catalytic box.
Prudent R; Cochet C
Chem Biol; 2009 Feb; 16(2):112-20. PubMed ID: 19246001
[TBL] [Abstract][Full Text] [Related]
12. The selectivity of inhibitors of protein kinase CK2: an update.
Pagano MA; Bain J; Kazimierczuk Z; Sarno S; Ruzzene M; Di Maira G; Elliott M; Orzeszko A; Cozza G; Meggio F; Pinna LA
Biochem J; 2008 Nov; 415(3):353-65. PubMed ID: 18588507
[TBL] [Abstract][Full Text] [Related]
13. Dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-4-ones as a new class of CK2 inhibitors.
Protopopov MV; Ostrynska OV; Starosyla SA; Vodolazhenko MA; Sirko SM; Gorobets NY; Bdzhola V; Desenko SM; Yarmoluk SM
Mol Divers; 2018 Nov; 22(4):991-998. PubMed ID: 29845490
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and evaluation of 3-quinoline carboxylic acids as new inhibitors of protein kinase CK2.
Syniugin AR; Ostrynska OV; Chekanov MO; Volynets GP; Starosyla SA; Bdzhola VG; Yarmoluk SM
J Enzyme Inhib Med Chem; 2016; 31(sup4):160-169. PubMed ID: 27590574
[TBL] [Abstract][Full Text] [Related]
15. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.
Leung KK; Shilton BH
Biochemistry; 2015 Jan; 54(1):47-59. PubMed ID: 25379648
[TBL] [Abstract][Full Text] [Related]
16. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases.
Chojnacki K; Wińska P; Wielechowska M; Łukowska-Chojnacka E; Tölzer C; Niefind K; Bretner M
Bioorg Chem; 2018 Oct; 80():266-275. PubMed ID: 29966873
[TBL] [Abstract][Full Text] [Related]
17. Development and exploitation of CK2 inhibitors.
Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
[TBL] [Abstract][Full Text] [Related]
18. Kinase CK2 inhibition: an update.
Cozza G; Pinna LA; Moro S
Curr Med Chem; 2013; 20(5):671-93. PubMed ID: 23210774
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, in vitro protoporphyrinogen oxidase inhibition, and herbicidal activity of N-(benzothiazol-5-yl)hexahydro-1H-isoindole-1,3-diones and N-(benzothiazol-5-yl)hexahydro-1H-isoindol-1-ones.
Wu QY; Jiang LL; Zuo Y; Wang ZF; Xi Z; Yang GF
Chem Biol Drug Des; 2014 Oct; 84(4):431-42. PubMed ID: 24803371
[TBL] [Abstract][Full Text] [Related]
20. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
Pardhi T; Vasu K
J Biomol Struct Dyn; 2018 Jan; 36(1):177-194. PubMed ID: 27960601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
